Hyper Insight™ – CTA Aneurysm
Hyper Insight™ Stroke AI
One platform across the stroke pathway — hemorrhage, infarction, aneurysm, perfusion and 3D vascular imaging, on CT and MR. One solution is FDA-cleared today; seven more are in the FDA process. Select any solution for its description, capabilities, and performance evidence.
Hyper Insight™ – CTA Aneurysm
CTALaunched · KRMFDS ApprovedFDA in ProgressPre-FDA Access
Detects and localizes unruptured intracranial aneurysms on brain CTA, with ROI visualization and size quantification — including lesions smaller than 3 mm.
Capabilities
- AI-powered aneurysm detection on CTA
- Comprehensive morphology analysis — shape & size characterization
- High-precision visualization — detects lesions under 3 mm
- 3D rendering
- Report with measurements
CTAAneurysm DetectionLocalizationROI VisualizationShape & Size Characterization3D RenderingReport
Performance & evidence
Sensitivity by aneurysm size (human → AI): 3–4 mm 66.00→87.30% (+21.30%p) · 5–10 mm 84.00→93.07% (+9.07%p) · ≥10 mm 99.00→99.99%.
Per-lesion: Accuracy 86.87% · Sensitivity 84.36% · Specificity 92.56%
⚠ Latest internal validation results
What it means clinically
- Diagnostic equity: non-radiology physicians gained +22.28pp sensitivity with AI (43.54%→65.82%) — the largest gain of all three reader groups, addressing mixed-reader teams, teleradiology platforms and rural networks.